The HHS on Thursday delayed until 2023 a Trump administration rule that would have altered payments from drugmakers to pharmacy middlemen.
The postponement follows a court order that also holds litigation about the rule in abeyance pending a review by the Department of Health and Human Services.
A pharmacy liaison group argued the changes would significantly disrupt negotiations with drugmakers.
The rule (0936-AA08), which changes payments to pharmacy benefit managers such that they can’t fluctuate based on the price of a drug, was slated to take effect January 2022. Judge John D. Bates of the U.S. District Court for the ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.